Ignite Creation Date:
2025-12-24 @ 7:34 PM
Ignite Modification Date:
2025-12-25 @ 5:15 PM
Study NCT ID:
NCT02937103
Status:
UNKNOWN
Last Update Posted:
2019-06-25
First Post:
2016-10-14
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Clinical Research of CD123-Targeted CAR-T in Myeloid Malignancies
Sponsor:
Southwest Hospital, China
Organization:
Study Overview
Official Title:
A Clinical Research of CD123-Targeted CAR-T in Myeloid Malignancies
Status:
UNKNOWN
Status Verified Date:
2019-06
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The overall purpose of this study is to explore the therapeutic effect of CD123-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of Myeloid Malignancies.
Detailed Description:
Great progress has been made in the treatment of relapsed and refractory B cell malignancies with CD19-targeted CAR-T cells. However, for myeloid malignancies, which has higher morbidity, trials of CAR-T is few. CD123 is expressed on most myeloid leukemia cells so it is a ideal target for CAR-T. Some researches have revealed that CD123 is a marker of leukemia stem cells, which indicates that the eradication of CD123+ cells may prevent relapse of leukemia. This trial is designed and conducted to test the safety and effectiveness of CD123-targeted CAR-T.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: